MET and non-small cell lung carcinoma: From a small phase II trial of capmatinib in 20 patients with METex14 NSCLC after crizotinib treatment, among the sixteen patients with detectable ctDNA, five (31%) had acquired MET mutations, three (19%) had MAPK pathway alterations, and two (13%) had ERBB pathway alterations [104].